Symptom Assessment of Patients following Percutaneous Transesophageal Gastrostomy Tube Placement

Overview

About this study

The purpose of this study is to measure the symptom response in patients with malignant bowel obstruction who have placement of a percutaneous transesophageal gastrostomy tube.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Age ≥18 years
Life expectancy of 2 weeks or greater
Patient must have regular access to a telephone
Histologically proven malignancy
Patient has clinical evidence of malignant bowel obstruction
Patient has contraindication for placement of PEG tube
Provision of informed consent
Able to complete patient questionnaire alone or with assistance. Participants must be able to speak and read English.
May receive chemo or radiation and hormonal therapy while on study

Exclusion Criteria:

Obvious cognitive dysfunction
Study will exclude women who are pregnant and/or nursing
Presence of tracheal fistula
Previous or scheduled therapy for the neck.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Mark Edwin, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mark Edwin, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials